Article Text
PDF
Abstract
Objectives To identify clinical characteristics of patients with non-refractory Kawasaki disease (KD), which were defined as those who successfully responded to the standard initial intravenous immunoglobulin (IVIG) treatment (2 g/kg/day, single infusion) without any secondary or later additional specific treatments, and to investigate the factors associated with the development of coronary artery (CA) complications in patients with non-refractory KD.
Design Retrospective cohort study.
Setting Hospitals specialising in paediatrics and hospitals with ≥100 beds and a paediatric department throughout Japan.
Patients A total of 122 489 patients who developed KD across Japan during 2011–2018.
Main outcome measures CA abnormalities identified after acute illness of KD (defined as CA sequelae).
Results A total of 69 735 patients with non-refractory KD were identified, of which 672 (0.96%) experienced CA sequelae. Among patients with non-refractory KD, the presence of CA abnormalities identified at initial echocardiographic assessment was strongly associated with CA sequelae (adjusted OR (95% CI): 37.8 (31.9 to 44.7)). CA sequelae was also associated with male patients, infants (<12 months old), older patients (≥60 months old) and patients who received delayed initial IVIG treatment (>7 days from KD onset). Subgroup analyses demonstrated that delayed initial IVIG treatment was significantly associated with the development of CA sequelae in both patients with and without CA abnormalities identified at initial echocardiographic assessment.
Conclusions Approximately 1% of patients with non-refractory KD may develop CA sequelae. Our findings highlight the importance of initial echocardiographic assessment and early initiation of IVIG treatments for patients with KD.
- Epidemiology
- Paediatrics
- Cardiology
Data availability statement
Data are available upon reasonable request. De-identified patient data and the full dataset with low risk of identification may be available on reasonable request from the corresponding author.
Statistics from Altmetric.com
Data availability statement
Data are available upon reasonable request. De-identified patient data and the full dataset with low risk of identification may be available on reasonable request from the corresponding author.
Footnotes
Contributors ST, RA, TK, MK and NK contributed to the study conception and design. Data acquisition and database management were performed by RA, KK and MK. ST, RA, TK, NK and MK contributed to the analysis. The first draft of the manuscript was written by ST and RA. All authors contributed to the interpretation, revised the manuscript critically and approved the final version for submission. RA is the overall guarantor.
Funding RA acknowledges funding from grants and funding from a non-profit organization, the Japan Kawasaki Disease Research Center. The funder played no active role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; or decision to submit the manuscript for publication.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.